Details for Patent: 12,128,059
Which drugs does patent 12,128,059 protect, and when does it expire?
Patent 12,128,059 protects CABTREO and is included in one NDA.
This patent has twelve patent family members in ten countries.
Summary for Patent: 12,128,059
| Title: | Topical compositions |
| Abstract: | The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same. |
| Inventor(s): | Varsha Bhatt, Radhakrishnan Pillai, Arturo Angel |
| Assignee: | Bausch Health Ireland Ltd |
| Application Number: | US17/835,935 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 12,128,059 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
| Patent landscape, scope, and claims: | Scope & Claims Review and U.S. Patent Landscape for United States Drug Patent 12,128,059 (Clindamycin Phosphate + Benzoyl Peroxide + Adapalene Topical Gel) Executive summary
What claims does US 12,128,059 cover for a clindamycin phosphate, benzoyl peroxide, adapalene topical gel?Bottom line: Independent claim 1 is the central infringement anchor. Dependent claims narrow to specific wt% embodiments, specific gelling agents (carbomer Type C, crosslinked carboxylate polymers), and specific microstructure/compatibility features. Downstream method, container, and manufacturing claims create multiple infringement pathways. Claim 1 (composition): what is required to infringeA topical gel formulation comprising:
Gelling agent genus (selected from): hydroxypropylcellulose, hydroxyethylcellulose, carboxyvinyl polymers, crosslinked carboxyvinyl polymers with allyl ethers of polyalcohols, carboxyvinyl copolymers, polyacrylates, acrylate copolymers, acrylamide/sodium acryloyldimethyltaurate copolymers, polyvinyl alcohols, polyethylene oxides, propylene glycol alginates, methylcellulose, hydroxypropylmethylcellulose, xanthan gum, carrageenan gum, and combinations. Infringement posture:
Claim 2 and 3 (preferred numerical targets)
Practical meaning: These dependent claims pin down a lead formulation with a carbomer Type C gel matrix, an alkaline pH window, and propylene glycol as the polyhydric alcohol system. Claims 4–7 (method of treating acne)
Evidentiary posture: Claim 7 sets up a litigation-friendly efficacy differentiation that can be attacked by designing clinical endpoints or by arguing the claim requires a specific comparative finding. Claim 8 (drug container/pump dispensing)
Risk implication: Even if composition is close, product packaging/labeling that enforces a fixed-dose pump could draw in additional defendants (manufacturer or packager) if the pump is integral to the “specific amount” calibration. Claim 9 (making the gel: premix steps)A multi-step method:
Infringement posture: Process claims are typically harder to prove without manufacturing records, but if a competitor uses the same premix logic (especially micronized adapalene dispersion in polyhydric alcohol and pH adjustment window), it can create discovery leverage. Which formulation features inside US 12,128,059 narrow infringement risk (gelling agent, pH, polyhydric alcohol)?Claim 10: carbomer homopolymer Type C
Design-around: switching to cellulose, natural gums, or non-carbomer acrylic systems avoids the specific dependent claim but may still infringe claim 1 if the new gelling agent remains in the claim-1 list. Claim 11: crosslinked carboxy polymer + base
Design-around: using non-carboxylate thickening polymers or avoiding the base-thickening mechanism may reduce literal fit (for claim 11), though claim 1 can still capture if the gelling agent remains listed. Claim 12: gelling agent amount 1.5–2 wt%A quantity limiter that targets a typical gel viscosity platform. Claims 16 and 18: polyhydric alcohol scope and amount
Design-around: using a polyhydric alcohol outside the named list or outside the wt% band targets dependent claim avoidance. Claim 1 still requires “a polyhydric alcohol” but not the same narrowed list; however, claim construction and dependent claims can influence how the rest of the claim set is read in practice. Claim 17: no additional organic solvents besides the polyhydric alcoholIf a competitor includes additional organic solvents, they may avoid claim 17 while still potentially falling within claim 1 if those solvents are “organic solvents other than polyhydric alcohol.” Claim 19: free of ionic surfactantsThis may matter for formulation stability and wetting. Avoiding ionic surfactants is a straightforward design-around for claim 19, but the broader claim 1 does not require surfactant absence. How do the “undissolved particle size” and “no oxidation” limitations affect infringement and generic entry risk?Claim 13: undissolved benzoyl peroxide with 1–50 micron mean particle size
Competitive impact:
Claim 14: optional undissolved adapalene fraction
Impact: This is likely a second microstructure hook that can be evaluated via microscopy/particle size distribution. Claim 15: adapalene and benzoyl peroxide do not undergo oxidation reactionThis is an explicit compatibility/chemical stability constraint. Risk: Competitors may reformulate but must demonstrate the “no oxidation” condition. In litigation, this becomes a test-question framed around analytical stability outcomes under relevant storage/usage conditions. If a competitor’s formulation shows measurable oxidation products, it may fail the dependent claim 15. How strong is the patent estate for competitors: what are the main infringement theories built into US 12,128,059?Structure of enforcement leverage in the provided claims:
Practical strength drivers:
What patents likely intersect with US 12,128,059’s scope (and where are the typical gaps)?A complete U.S. landscape cannot be produced from the claim text alone because no bibliographic data (publication numbers, filing date, expiration, assignee, related continuations, citation set) is provided here. The following is limited to claim-logic intersections that commonly occur in the same therapeutic and formulation domain. Potential intersection clusters implied by the claim set
Where gaps usually appear
What would a design-around have to change to avoid claim 1 and its core dependents?To avoid claim 1 literal infringement, a competitor generally must change at least one of the major pillars:
To avoid the strongest dependent claims without changing the core, a competitor may target:
Key Takeaways
FAQs
References
More… ↓ |
Drugs Protected by US Patent 12,128,059
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch | CABTREO | adapalene; benzoyl peroxide; clindamycin phosphate | GEL;TOPICAL | 216632-001 | Oct 20, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,128,059
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2020322173 | ⤷ Start Trial | |||
| Canada | 3149296 | ⤷ Start Trial | |||
| China | 114126582 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
